12
Apr
2023

Function Gets $28M to Make Personalized Cancer Genomics to the Next Level

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Investing in Biotech & Healthcare Delivery: Vineeta Agarwala on The Long Run
Physician-Scientist-Biotech VC: Vineeta Agarwala on The Long Run
Knowledge is Power: Don’t Give Up on Diagnostic Tests for COVID19
A16Z Rakes in New $450M Fund to Build ‘Engineering Biology’ Plays